The DecisionDx-Melanoma test accurately identifies low sentinel lymph node risk in melanoma, according to the DECIDE study.

Castle Biosciences (CSTL) announced the recent publication of two papers in the World Journal of Surgical Oncology and Cancer Medicine sharing ...

The next update on the Phase 1a trial with clinical data at relevant dose levels in second-line and later melanoma is planned in 2025. Immatics is further harnessing the potential of its ...